Lower Extremity Arterial Disease Event Reduction Trial - LEADER

Description:

The goal of the Lower Extremity Arterial Disease Event Reduction (LEADER) trial was to assess the effect of bezafibrate on the risk of coronary heart disease (CHD) and stroke in men with lower extremity arterial disease.